5 insightful analyst questions from McKesson’s Q3 CY2026 earnings call
McKesson’s results in the third quarter reflected continued momentum in its core pharmaceutical distribution and specialty services. Management highlighted strong performance from North American Pharmaceutical and Oncology & Multispecialty, driven by higher prescription volume—including GLP-1 medications—and provider platform growth. CEO Brian Tyler underscored the strategic value of recent acquisitions, noting, “Our acquisition of Precision Medicine Group adds global clinical research and commercialization capabilities, expanding our ability to support biopharma partners.” While operational leverage and diversified growth supported non-GAAP earnings, the company faced headwinds from lower branded pharmaceutical pricing and branded-to-generic conversions, which partially offset top-line gains.
Is now the time to buy MCK? Find out in our full research report (it’s free for active Edge members).
McKesson (MCK) Q3 CY2026 highlights:
- Revenue $111 billion vs S&P analysts’ estimates of $110.1 billion (7.6% year-on-year growth, 0.8% beat)
- Adjusted EPS $11.68 vs S&P analysts’ estimates of $10.75 (8.6% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $46 at the midpoint, a 3.1% increase
- Operating margin 1.4%, in line with the same quarter last year
- Market capitalization $123.8 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from McKesson’s Q3 earnings call
- Glen Santangelo (Barclays) asked how Precision Medicine Group and Option Care Health would affect segment margins and reporting. CFO Kenny Cheung explained PMG would be consolidated into Oncology & Multispecialty, while Option Care Health would be accounted for under the equity method and not impact segment margins.
- Brian Tanquilut (Jefferies) inquired about strategic overlap between Option Care Health and McKesson’s oncology business. CEO Brian Tyler said the deal enhances access to specialty and rare disease therapies in community and home settings, complementing existing assets.
- Elizabeth Anderson (Evercore) pressed on the sustainability of above-trend growth in North American Pharmaceutical. Cheung attributed it to broad-based volume growth, specialty product demand, and operational excellence, but flagged that investments and market trends will shape future performance.
- Lisa Gill (JPMorgan) questioned the impact of potential 340B policy changes on pharmaceutical volumes. Tyler said McKesson’s presence across channels positions it to adapt, though customer behavior and regulatory outcomes remain uncertain.
- Allen Lutz (Bank of America) sought clarity on the integration complexity of recent acquisitions versus prior deals. Tyler described the acquisitions as highly complementary with minimal overlap, and Cheung noted Option Care Health will run semi-autonomously under a partner-led model.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will be watching (1) the pace and financial impact of integrating Precision Medicine Group into Oncology & Multispecialty, (2) progress toward closing and operationalizing the Option Care Health investment, and (3) the resilience of specialty pharmaceutical demand, especially GLP-1s, amid potential policy changes. Developments in the regulatory environment and customer contract renewals will also serve as important indicators of execution.
McKesson currently trades at $1,068, in line with $1,067 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.